KUALA LUMPUR, June 28 — CGS-CIMB Securities Sdn Bhd is positive on Pharmaniaga Bhd on the expectation of a decent financial year 2023-2024 earnings growth for the company.
“The ample excess production capacity at Pharmaniaga’s existing plants will allow it to ramp up output in the next three to five years — in light of rising pharmaceutical demand and new product launches — with little to no incremental capital expenditure, thus potentially leading to better economies of scale and margins,” it said.
Singapore Singapore Latest News, Singapore Singapore Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: staronline - 🏆 4. / 75 Read more »